Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review |
| |
| Authors: | Chih-Jen Yang Yu-Jui Wei Hsu-Liang Chang Pi-Yu Chang Chung-Chen Tsai Yen-Hsu Chen Po-Ren Hsueh |
| |
| Affiliation: | 1. Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan;2. Department of Management, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan;3. Department of Medical Information of Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan;4. School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan;5. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan;6. Department of Biological Science and Technology, College of Biological Science and Technology, National Chiao Tung University, Hsin-Chu, Taiwan;7. Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan;8. Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan |
| |
| Abstract: | ![]()
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative viral pathogen of coronavirus disease 2019 (COVID-19), appears to have various clinical presentations and may result in severe respiratory failure. The global SARS-CoV-2-associated viral pneumonia pandemic was first reported in December 2019 in China. Based on known pharmacological mechanisms, many therapeutic drugs have been repurposed to target SARS-CoV-2. Among these drugs, remdesivir appears to be the currently most promising according to several clinical trials and reports of compassionate use. In this mini-review, we summarize the current evidence on the efficacy and challenges of remdesivir for the treatment of coronavirus disease 2019 (COVID-19). |
| |
| Keywords: | Severe acute respiratory syndrome coronavirus 2 Coronavirus disease 2019 Remdesivir Compassionate use |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
